"The trouble is that the market is changing much faster than most marketers realize."
Roche strikes out in cancer, Alzheimer's trials; Lilly in pact for fast-acting insulin; Humana revamps formulary.
The company moves on three leading contenders in the muscular dystrophy segment with the start of a Phase II trial
The FDA's prescription drug promotion arm wrote that the professional print ad for seizure med Aptiom "misleadingly overstated its efficacy."
Canadian firm presents FDA with its third biosimilar application.
The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million
Shire may bid on NPS Pharmaceuticals; Amgen says cancer drug will cost $178,000; Takeda has a new head of R&D.
Pfizer has kicked off a disease-awareness campaign, "Take Action Against Meningitis," urging parents to discuss vaccinations with their healthcare providers with paralympic snowboarder Amy Purdy.
Ruling voids FDA's take on reissued patents, settling a year of challenges by generic applicants
The much hashed-over initiative would require pharma firms to distribute the professional insert electronically.
The annual awards show, celebrating creativity in marketing communications, has named Langland's executive creative director and Sudler & Hennessey chief creative officer to lead the jury.
UCB generic deal falls through; agency hiring could spike in 2015; teenage prescription drug abuse is on the decline.
Swiss drugmaker Novartis received an FDA nod for rare disease treatment Signifor LAR Tuesday, as orphan drug approvals reach new heights.
The driver on NASCAR and other racing circuits will help challenge consumers to improve their health habits.
Studies by Australian company Novogen are said to demonstrate, for the first time, that a drug highly effective against brain cancers has the same high potency against melanoma.
The new approach shows "The Talk" has a sequel.
Bayer consolidates OTC creative portfolio; Genentech R&D head steps down; Novartis receives approval for orphan drug.
The treatment reduces risk by half compared to widely used Zelboraf.
Court clears the way for a Nexavar generic from Natco
The drugmakers, who have an experimental cholesterol medication in the works, are asking consumers what they know about heart health.
The regulator noted in its early 2014 retrospective that it set a high mark for the number of approved rare disease drugs this year, and that insufficient information is the reason many breakthrough status requests get bounced.
United Healthcare tests an all-in-one cancer payment model, Pfizer inks a worldwide commercialization license for a human growth factor hormone, and the Commonwealth Fund grades Medicare as the program nears its 50th.
Judge rules Actavis must keep Alzheimer's drug on the market; Wyeth CEO joins Roche board, dispelling rumors he may be next Sanofi CEO; Two senators propose new FDA designation which would award 15 years of marketing exclusivity.
Cubist is re-launching its C.-Diff. antibiotic in an effort to jumpstart sales beyond Cubicin, which contributes most of its product revenue.
"Customer service is more than just a nice-to-have. In this competitive marketplace, it can mean the difference between your brand or someone else's."
Researchers found no difference between Lyrica (pregabalin) and placebo in treating lumbar spinal stenosis.
Interim CEO Serge Weinberg tells a German paper that the company is prepared to buy assets that meet its goal of providing stable, steady growth.
Philadelphia Transportation Authority sues Gilead over Sovaldi sticker shock; Digital marketing tactics raise privacy concerns; another patent cliff is on the horizon.
The snag: identifying what qualifies as download-worthy.
The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.
As courts sort out lawsuits over two Sandoz biosimilars, the Novartis unit reports a study showing its BLA candidate has similar efficacy to Neupogen.
Mylan, Teva, and Actavis announced generics of the $3 billion arthritis drug.
Cubist's best-selling product has four of its five patents invalidated; the first biologic of AbbVie's Humira launches in India; Mylan debuts generic Celebrex.
"We are living in an era of great medical technological innovations. However, this is shifting healthcare back home and expecting patients to understand excessive medical information and follow complex instructions."
An investigational JAK inhibitor, baricitinib, bested placebo in moderate to severe plaque psoriasis in a Phase-III trial.
Patient advocates lobbied the FDA to approve the MS drug and Sanofi subsidiary Genzyme says their voice will be part of the consumer outreach when DTC rolls out next year.
WSJ reported FDA advisors failed to disclose pharma financial ties; Novartis axes 200 employees in New Jersey; Takeda retires the Millennium brand.
Sun Pharma buys troubled Ranbaxy and its pipeline of promising follow-ons.
Merck's Keytruda and BMS's Opdivo reverse tumor growth in Hodgkin's patients studies.
MAHF 2015 Heritage Ad Awards will be given to campaigns for Bentyl, Hytrin and Navane
Early trials of Venetoclax, formerly known as ABT-199, indicate the experimental drug execs consider an oncology cornerstone continues to show promise.
Merck buys up Cubist in an $8.4B deal, a jury sides with AstraZeneca in a generic Nexium lawsuit and the NYT finds a correlation between Genentech payments and Lucentis prescriptions.
"In this era, it requires mobilizing our collective intelligence toward innovation and integration that is meaningful for large populations."
GSK opts to hold onto $1.6 billion portfolio of older drugs; Sanofi upheavals continue with exit of US diabetes sales exec; Takeda gains breakthrough status on AL amyloidosis therapy.
Transfer of rights to the experimental cancer drug hinges on completion of Novartis/GSK asset swap.
Members of the 13-32 age group were less likely to agree that preventive care is the most important factor in staying healthy, compared to Baby Boomers and Gen-Xers.
Jakafi becomes the first drug approved for treating polycythemia vera.
Doctors tell investment firm Leerink they don't anticipate upping their prescriptions of the new Ellipta line.
Despite drugmaker discount, VA still can't afford Sovaldi without additional funds; Ousted Sanofi CEO Viehbacher faces lawsuit for an alleged kickback scheme; GSK slims sales and R&D workforce.
CureClick, TrialReach and WEGO team to leverage health communities and speed trial recruitment.
The bad news: heroin-related deaths inched upwards.
Amgen's Blincyto was approved for a rare form of leukemia after receiving Breakthrough Therapy designation and a Priority Review.
The drugmaker inked a deal with Zosano worth up to $440 million for the product, which is about to enter Phase-III in clinical trials.
An Italian court backs the anti-trust's stand that Novartis and Roche colluded in Lucentis marketing; AstraZeneca is the test case for the court's new interpretation of pay-for-delay; early-stage results prompt Biogen Idec to take its experimental Alzheimer's treatment to Phase-III.
As patients spend more time in waiting rooms where they are primed to learn about their health, POC promotions are becoming a more essential part of the marketing mix, researchers find.
More cost data for the file the latest data shows that up-front healthcare costs are prompting many patients to delay office visits.
The first low-cost version of the Shire ADHD drug benefits as a first-filer.
Otsuka acquires Avanir; hackers target pharma; Novartis must give up nicotine patch to finalize GSK consumer deal.
The approval adds a second option to a category that Medtronic has had to itself since 2006.
US filing in hand, the company expects to submit drug for EMA approval in 2016.
Novartis released Phase-III study results Monday.
The number of new HIV cases has held steady since the 1990s. Researchers note it is progress of a sort, but that driving numbers down requires one basic step: testing, testing, testing.
GSK is set to announce US job cuts this week, sales reps are getting the axe in China, and the FDA has rejected Avanir's inhalable migraine medication.
President, Advertising, inVentiv Health
There needs to be a greater effort put into the issue of adherence. What can academia, providers, pharma and payers do to address this pressing need?
Once we venerated doctors. Now we question every dollar they make
LabCorp's purchase of CRO Covance promises to open access to LabCorp's patient database for trial recruiting. Can this help resolve problems like the disparity of female representation and scarcity of subjects for studies?
Ruby Gadelrab. VP, commercial marketing, 23andMe
Tecfidera's visual pun fails to deliver Biogen's message
I come not to bury government but to praise it—at least the singular agency I know best: FDA
Running clinical trials remains one of Big Pharma's biggest headaches. But thanks to canny use of social media, gamification techniques and even text messages, CROs have revitalized and revolutionized the process. Barbara Peck explains
Programmatic ad buying hasn't exactly taken over the industry, but its approach has precipitated a paradigm shift, media experts say.
Click the above link to access the complete Digital Edition of the December 2014 issue of MM&M, with all text, charts and pictures.
To mark the 27th annual World AIDS Day on Monday, Treato prepared an infographic showing patient insights about the ongoing fight against the disease. Among them: while posts about infection decreased last year, discussions about prevention more than doubled.
FDA issued a complete response letter on daclatasvir.
United Healthcare's Baby Blocks app seeks to become all-in-one hub for expectant moms and their babies.
An advisory panel voted against adding warnings to steroid injection labels.
The agency sent a Warning Letter to three marketers over their use of metatags in search engine marketing tactics.
Tecfidera gets label change; Amgen and AstraZeneca report psoriasis Phase-III antibody results; JAMA study reinforces statin guidelines.
Encouraging competitors to take an artistic approach to "Breathless Moments," the competition is a first for Bayer, which is already working on next year's effort.
The scientist is also banned from receiving federal funding.
The German firm positions to focus on pharma pipeline and animal health.
Onexton is a first-and-only drug combination for treating acne.
AstraZeneca and Ranbaxy pay-for-delay case marches on; FDA extends Novartis multiple myeloma Priority Review timeline; Endo pays $25 for testosterone nasal gel.
Complementary solutions to drive growth with health plans as well as pharma clients, companies say.
The Center for Drug Evaluation and Research's director says there is a need for new opioids and cuts off dosing comparisons between extended-release and immediate-release opioids.
The north-of-the-border solution comes amid climbing heroin abuse in the US.
The reason: coordination and effectiveness.
BioMarin to acquire Dutch biotech Prosensa; Woodcock says significant efficacy key to Breakthrough Therapy designation; Stryker considers $16 billion bid for UK devicemaker Smith and Nephew.
EMA revises its conflict of interest policy; AbbVie all-oral HCV combo drug receives positive EU recommendation; Merck may help NewLink Genetics scale production of its Ebola vaccine.
In a company-hosted seminar today, the Paris-based drugmaker gave investors a preview of the future of its diabetes franchise.
The first approved hydrocodone formulated to discourage misuse raises a challenge to controversial Zohydro.
The IMS Institute for Healthcare Informatics notes that developed markets remain a key driver.
CRS asks if high prices are a tool to offset CMS rebates, the FDA adds another DTC study to its lineup, and the NIH proposes making more clinical trial data public.
With the purchase of Olson Communications, the agency aims to serve clients eager for expertise from outside the healthcare industry.
Success today is predicated on recognizing that every patient is different, every disease is different, every drug, every breakthrough and every cure is different.
Drug makers favor big spending on speakers' events and doctor outreach.
The scoop means the maker of HCV drugs Harvoni and Sovaldi can give any drug an accelerated review time.
Sanofi vets Takeda, devicemaker CEO candidates; Shaq returns for IcyHot; Royalty Pharma buys royalties on Vertex's Kalydeco.
Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.